TP53 and hepatocellular carcinoma: Especially in early HCC tumor stages, stage I and II, the tumors with TP53 missense mutations appeared to have lower levels of VIM methylation than the tumors with wild type TP53 (S4 Fig), but the association remained statistically non-significant, possibly due to relatively small numbers.